Literature DB >> 8618014

97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane.

A Ishiko1, H Shimizu, T Masunaga, T Hashimoto, M Dmochowski, F Wojnarowska, B S Bhogal, M M Black, T Nishikawa.   

Abstract

Linear IgA bullous dermatosis (LAD) is an autoimmune blistering disease in which IgA autoantibodies develop against the epidermal basement membrane zone. Target antigens of the circulating autoantibodies are thought to be heterogeneous, and their ultrastructural localization has not been fully elucidated. Previous studies with immunoblotting have demonstrated that the 97-kDa autoantigen is detected most frequently in patients' sera and is thought to be a major LAD antigen. Although a recent report suggests that the 97-kDa antigen localized to the hemidesmosomal plaques and the adjacent lamina lucida, discrepancies still exist among previous immunoelectron microscopic findings. To identify the precise localization of the 97-kDa LAD antigen, we used two different low-temperature immunoelectron microscopic techniques. For immunolabeling, we selected five LAD sera that had a high titer of autoantibodies against the 97-kDa LAD antigen. A post-embedding method with cryofixation and freeze substitution failed to immunolabel the 97-kDa LAD antigen. Cryoultramicrotomy with immunoelectron microscopy succeeded in preserving the antigenicity of the 97-kDa LAD antigen. In all cases, the majority of labeling occurred in the lamina lucida beneath the hemidesmosomes. No specific labeling was observed in the hemidesmosomal attachment plaques or the lamina densa or sublamina densa region, including anchoring fibrils. These results indicate that the 97-kDa LAD antigen is a component of the lamina lucida.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618014     DOI: 10.1111/1523-1747.ep12345793

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  [Chronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone].

Authors:  D Pirkhammer; D Zillikens; D Födinger; P Zimmermann; K Rappersberger
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

Review 2.  What's new in blistering disorders?

Authors:  Paru Chaudhari; M Peter Marinkovich
Journal:  Curr Allergy Asthma Rep       Date:  2007-07       Impact factor: 4.806

3.  Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis.

Authors:  Atsunari Tsuchisaka; Koji Ohara; Norito Ishii; Ngon T Nguyen; M Peter Marinkovich; Takashi Hashimoto
Journal:  J Invest Dermatol       Date:  2014-09-10       Impact factor: 8.551

4.  Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

5.  Bullous Dermatosis in an End-Stage Renal Disease Patient: A Case Report and Literature Review.

Authors:  Zeenat Yousuf Bhat; Marwan Abu Minshar; Nashat Imran; Andrew Thompson; Yahya Osman Malik
Journal:  Case Rep Nephrol       Date:  2016-11-24

Review 6.  Diagnostics of autoimmune blistering disorders: an experience of a single tertiary referral centre.

Authors:  Alicja Adaszewska; Katarzyna Woźniak; Agnieszka Kalińska-Bienias; Katarzyna Smolarczyk; Cezary Kowalewski
Journal:  Postepy Dermatol Alergol       Date:  2020-11-04       Impact factor: 1.664

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.